MX2017015202A - Formulaciones liquidas de celecoxib para administracion oral. - Google Patents
Formulaciones liquidas de celecoxib para administracion oral.Info
- Publication number
- MX2017015202A MX2017015202A MX2017015202A MX2017015202A MX2017015202A MX 2017015202 A MX2017015202 A MX 2017015202A MX 2017015202 A MX2017015202 A MX 2017015202A MX 2017015202 A MX2017015202 A MX 2017015202A MX 2017015202 A MX2017015202 A MX 2017015202A
- Authority
- MX
- Mexico
- Prior art keywords
- celecoxib
- oral administration
- liquid formulations
- solution
- insolubility
- Prior art date
Links
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 title abstract 5
- 229960000590 celecoxib Drugs 0.000 title abstract 5
- 239000012669 liquid formulation Substances 0.000 title 1
- 239000000725 suspension Substances 0.000 abstract 2
- 239000008297 liquid dosage form Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562168012P | 2015-05-29 | 2015-05-29 | |
| US15/163,258 US20160346300A1 (en) | 2015-05-29 | 2016-05-24 | Liquid formulations of celecoxib for oral administration |
| PCT/US2016/033937 WO2016196085A1 (en) | 2015-05-29 | 2016-05-24 | Liquid formulations of celecoxib for oral administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017015202A true MX2017015202A (es) | 2018-07-06 |
Family
ID=57396976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017015202A MX2017015202A (es) | 2015-05-29 | 2016-05-24 | Formulaciones liquidas de celecoxib para administracion oral. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20160346300A1 (enExample) |
| EP (1) | EP3302430A4 (enExample) |
| JP (1) | JP2018516279A (enExample) |
| AU (1) | AU2016270504A1 (enExample) |
| BR (1) | BR112017025527A2 (enExample) |
| CA (1) | CA2987388A1 (enExample) |
| MX (1) | MX2017015202A (enExample) |
| RU (1) | RU2017145602A (enExample) |
| WO (1) | WO2016196085A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6605047B2 (ja) * | 2015-05-28 | 2019-11-13 | ドクター・レディーズ・ラボラトリーズ・リミテッド | 疼痛治療のためのセレコキシブの経口用組成物 |
| WO2022185338A1 (en) * | 2021-03-05 | 2022-09-09 | Alkem Laboratories Limited | Stable oral suspension of celecoxib and method of preparation thereof |
| CN115737554B (zh) * | 2022-11-28 | 2024-07-09 | 宜昌人福药业有限责任公司 | 一种氯巴占口服混悬剂的制备方法 |
| WO2024142089A1 (en) * | 2022-12-27 | 2024-07-04 | Cipla Limited | Injectable compositions of celecoxib |
| US12678405B1 (en) | 2025-07-29 | 2026-07-14 | Codadose Incorporated | Oral liquid compositions of celecoxib |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4145440A (en) * | 1977-08-18 | 1979-03-20 | The Upjohn Company | Liquid suspension of an aluminum salt of ibuprofen |
| IN191512B (enExample) * | 2000-01-21 | 2003-12-06 | Panacea Biotech | |
| CA2406226A1 (en) * | 2000-04-18 | 2001-10-25 | Pharmacia Corporation | Rapid-onset formulation of a selective cyclooxigenase-2 |
| AR035642A1 (es) * | 2000-05-26 | 2004-06-23 | Pharmacia Corp | Uso de una composicion de celecoxib para el alivio rapido del dolor |
| US6656505B2 (en) * | 2000-07-21 | 2003-12-02 | Alpharma Uspd Inc. | Method for forming an aqueous flocculated suspension |
| US20030105144A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
| UA80682C2 (en) * | 2001-08-06 | 2007-10-25 | Pharmacia Corp | Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition |
| US7101572B2 (en) * | 2001-12-07 | 2006-09-05 | Unilab Pharmatech, Ltd. | Taste masked aqueous liquid pharmaceutical composition |
| US20030157172A1 (en) * | 2001-12-20 | 2003-08-21 | Lu Guang Wei | Pharmaceutical suspension for oral administration |
| ATE541562T1 (de) * | 2002-06-17 | 2012-02-15 | Taro Pharmaceuticals Usa Inc | Ibuprofen-suspension |
| WO2004047752A2 (en) * | 2002-11-26 | 2004-06-10 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations of celcoxib |
| WO2005009342A2 (en) * | 2003-07-16 | 2005-02-03 | Pharmacia Corporation | Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith |
| US20050266031A1 (en) * | 2004-05-25 | 2005-12-01 | Jay Dickerson | Pharmaceutical suspension composition |
| US20080014274A1 (en) * | 2006-07-14 | 2008-01-17 | Wyeth | Enhanced stability phenylephrine liquid compositions |
| US20110183944A1 (en) * | 2010-01-28 | 2011-07-28 | Paul Ashton | SUSTAINED-RELEASE NSAID/HMG CoA REDUCTASE INHIBITOR COMPOSITIONS |
| EP3530268B1 (en) * | 2012-10-09 | 2021-12-15 | Attentive Therapeutics, Inc. | Therapeutic treatment |
| CN103932977A (zh) * | 2014-04-15 | 2014-07-23 | 江苏正大清江制药有限公司 | 一种塞来昔布制剂的制备方法 |
-
2016
- 2016-05-24 JP JP2018513730A patent/JP2018516279A/ja active Pending
- 2016-05-24 AU AU2016270504A patent/AU2016270504A1/en not_active Abandoned
- 2016-05-24 BR BR112017025527A patent/BR112017025527A2/pt not_active Application Discontinuation
- 2016-05-24 MX MX2017015202A patent/MX2017015202A/es unknown
- 2016-05-24 EP EP16804009.5A patent/EP3302430A4/en not_active Withdrawn
- 2016-05-24 WO PCT/US2016/033937 patent/WO2016196085A1/en not_active Ceased
- 2016-05-24 RU RU2017145602A patent/RU2017145602A/ru not_active Application Discontinuation
- 2016-05-24 CA CA2987388A patent/CA2987388A1/en not_active Abandoned
- 2016-05-24 US US15/163,258 patent/US20160346300A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017145602A3 (enExample) | 2019-11-25 |
| CA2987388A1 (en) | 2016-12-08 |
| BR112017025527A2 (pt) | 2018-08-07 |
| RU2017145602A (ru) | 2019-07-02 |
| EP3302430A4 (en) | 2019-05-29 |
| AU2016270504A1 (en) | 2017-12-14 |
| EP3302430A1 (en) | 2018-04-11 |
| JP2018516279A (ja) | 2018-06-21 |
| US20160346300A1 (en) | 2016-12-01 |
| WO2016196085A1 (en) | 2016-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201691151A1 (ru) | Соединения для лечения пациентов с ros1-мутантными раковыми клетками | |
| CR20200152A (es) | DERIVADOS DE INDOL MONO-O-DI-SUSTITUIDOS COMO INHIBIDORES DE LA REPLICACIÓN VIRAL DEL DENGUE (Divisonal 2017-0490) | |
| PH12018502077A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| MX389592B (es) | Moduladores alostericos positivos del receptor m1 muscarinico | |
| MX2018011788A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. | |
| CR20200291A (es) | Composiciones y métodos para el tratamiento de enfermedades metabólicas | |
| MX2018011784A (es) | Derivados de indol sustituidos como inhibidores de la replicacion virica del dengue. | |
| PH12015502628A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| EA201790726A1 (ru) | Фармацевтическая композиция для лечения язвенного колита | |
| NZ721780A (en) | Heterocyclic modulators of lipid synthesis for use against cancer and viral infections | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| EA201790949A1 (ru) | Замещенные 2,4-диаминохинолины в качестве новых противораковых средств | |
| BR112017025527A2 (pt) | preparação farmacêutica líquida, e, método para fabricar uma suspensão de celocoxibe. | |
| WO2015125152A3 (en) | Pharmaceutical compositions of asenapine | |
| AR090073A1 (es) | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos | |
| EA201500669A1 (ru) | Офтальмологическая фармацевтическая композиция для наружного применения, содержащая регорафениб | |
| NZ740587A (en) | Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators | |
| EA201990550A1 (ru) | Офтальмологический препарат, включающий азоловое соединение | |
| EA201892157A1 (ru) | Фосфаплатиновые жидкие составы | |
| EA201792170A1 (ru) | Производные индола | |
| EA201500446A1 (ru) | Фармацевтическая композиция для снижения уровня n-оксида триметиламина | |
| EA201891027A1 (ru) | Фармацевтическая композиция, содержащая производные индола, способ ее получения и применение | |
| MX2016017315A (es) | Formas de dosificacion farmaceutica. | |
| EA201600411A1 (ru) | Производные пиперидина для применения при лечении или профилактики психиатрических и неврологических состояний | |
| RU2013127881A (ru) | Применение фармацевтической композиции на основе соли четвертичного фосфония и замещенного динитробензофуроксана для лечения пироплазмоза у собак и способ лечения |